"Clinical trials for patients with rare diseases."

During the past decade, Rare Disease Research, LLC. conducted 47 clinical trials. In the 10-year time frame, 47 clinical trials started and 11 clinical trials were completed, i.e. on average, 23.4% percent of trials that started reached the finish line to date. In the past 5 years, 29 clinical trials started and 11 clinical trials were completed. i.e. 37.9% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Rare Disease Research, LLC." #1 sponsor was "Sarepta Therapeutics, Inc." with 8 trials, followed by "FibroGen" with 3 trials sponsored, "PTC Therapeutics" with 3 trials sponsored, "Biogen" with 2 trials sponsored and "Catabasis Pharmaceuticals" with 2 trials sponsored. Other sponsors include 26 different institutions and companies that sponsored additional 28 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Rare Disease Research, LLC." #1 collaborator was "Cromsource" with 1 trials as a collaborator, "Medpace, Inc." with 1 trials as a collaborator, "Ovid Therapeutics Inc." with 1 trials as a collaborator, "Sarepta Therapeutics, Inc." with 1 trials as a collaborator and "Syneos Health" with 1 trials as a collaborator. Other collaborators include -4 different institutions and companies that were collaborators in the rest 6 trials.

According to Clinical.Site data, the most researched conditions in "Rare Disease Research, LLC." are "Duchenne Muscular Dystrophy" (15 trials), "Muscular Dystrophy, Duchenne" (6 trials), "Duchenne Muscular Dystrophy (DMD)" (4 trials), "Spinal Muscular Atrophy" (3 trials) and "Epilepsy" (2 trials). Many other conditions were trialed in "Rare Disease Research, LLC." in a lesser frequency.

Most popular intervention types in "Rare Disease Research, LLC." are "Drug" (48 trials), "Other" (3 trials), "Biological" (2 trials) and "Combination Product" (1 trials). Other intervention types were less common.

The name of intervention was led by "Placebo" (18 trials), "Pamrevlumab" (3 trials), "SRP-5051" (3 trials), "Ataluren" (2 trials) and "Corticosteroids" (2 trials). Other intervention names were less common.

The vast majority of trials in "Rare Disease Research, LLC." are 27 trials for "Male" genders and 22 trials for "All" genders.

Currently, there are NaN active trials in "Rare Disease Research, LLC.". undefined are not yet recruiting, 16 are recruiting, 8 are Active, not recruiting, and 3 are Enrolling by invitation. In total, there were 12 completed trials in Rare Disease Research, LLC., undefined suspended trials, and 9 terminated clinical trials to date.

Out of the total trials that were conducted in Rare Disease Research, LLC., 6 "Phase 1" clinical trials were conducted, 20 "Phase 2" clinical trials and 26 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 3 trials, and there were also 0 trials that are defined as “Not Applicable".